GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ULTA · Jul 30, 2016

Ulta Beauty, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-16-691686General Corporate
Capex intensity60thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

8.91% · OPTIONAL · VALID

Revenue growth35thOwn-history percentile · N=17
Evidence method

Yoy · gp.fundamentals.revenue

21.92% · CORE · VALID

Gross margin65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

35.99% · CORE · VALID

Operating margin90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

13.45% · CORE · VALID

SBC intensity20thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.45% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History62 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Increased
Previous
5.06%
Current
8.91%
Delta
3.85%
Growth Decreased
Previous
23.68%
Current
21.92%
Delta
-1.77%
Margin Decreased
Previous
36.36%
Current
35.99%
Delta
-0.37%
Profitability Decreased
Previous
13.71%
Current
13.45%
Delta
-0.26%
Sbc Intensity Increased
Previous
0.37%
Current
0.45%
Delta
0.08%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.